Company leadership

Guiding research and innovation with expertise and vision

Abstract Image of Business People's Silhouettes in a Meeting

Revolutionising treatment
options for those living with
neurodegenerative diseases

Our leadership team and board bring together a wealth of experience in neuroscience, pharmaceutical development and corporate management. From research pioneers and industry executives to synthetic chemistry experts and accomplished anaesthetists, they contribute their diverse expertise to advance research and development in the field of neurodegenerative diseases.

C-Suite

Prof Claude Wischik

Co-Founder, Chairman and Chief Executive

Chief Operating Officer and Chief Business Officer

Prof Bjoern Schelter

Chief Analytics Officer

Dr Charles Harrington

Chief Scientific Officer and Head of Non-Clinical Development

Prof John Storey

Chief Technical Officer

Dr Richard Stefanacci

Chief Medical Officer

Directors

Dr Carol Pringle

Regulatory Director

Dr Diane Downie

Operations Director

Gavyn Barrett

Quality Assurance Director

Hwang Hong Wei

Finance Director

Lynn Rankin

People and Culture Director

Marcus Schembri-Wischik

Special Projects / Alternate Director / Data Protection Officer

Dr Sonya Miller

Medical Director

Department heads

Dr Alison Walker

Head of Operations Compliance

Carmen Irving

Head of UK Finance

Julie Reed

Head of IT and Infrastructure

Julie Gilbert

Head of Drug Supply Management

Kath Martin

Head of Data Science

Sid Salve

Head of Drug Safety

Dr Sotereos Gates

Head of Projects

Stephen Harte

Head of Legal

Dr Tom Baddeley

Head of Analytical Chemistry & DMPK

Andy Groundwater

Communications Lead

Further reading

Two man climbs a rock with rope. Sport climbing, lead.

Global partnerships have been essential in allowing us to reach a stage where a possible treatment for Alzheimer’s disease could be made widely available. Find out how you can be part of our mission.

Doctor or nurse caregiver with senior couple at home or nursing home

Clinical trials

TauRx recently completed its latest Phase III clinical trials in Alzheimer’s disease and in the rare neurodegenerative disorder, behavioural variant frontotemporal dementia (bvFTD).

AI brain light bulb concept. 3D render

Find out more about our pioneering drug, hydromethylthionine mesylate (HMTM), which could revolutionise treatment for Alzheimer’s and related diseases.